<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04845997</url>
  </required_header>
  <id_info>
    <org_study_id>02</org_study_id>
    <nct_id>NCT04845997</nct_id>
  </id_info>
  <brief_title>COVID-19 Vaccination in Patients With Rheumatic Diseases</brief_title>
  <acronym>SAR-CoVAC</acronym>
  <official_title>NATIONAL VACCINATION REGISTRY FOR SARS-CoV-2 IN PATIENTS WITH RHEUMATIC DISEASES OF THE ARGENTINE SOCIETY OF RHEUMATOLOGY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sociedad Argentina de Reumatologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sociedad Argentina de Reumatologia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Argentine Society of Rheumatology (SAR) set out to develop a national register of&#xD;
      patients with rheumatic diseases who have received a SARS-CoV-2 vaccine in order to assess&#xD;
      their efficacy and safety in this population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational, longitudinal, multicenter study, including patients with rheumatic&#xD;
      diseases who have been vaccinated for COVID-19 in Argentine or any country. Patients will be&#xD;
      followed for 12 months and two evaluations will be performed, one at baseline and the other&#xD;
      after the follow-up time is completed.&#xD;
&#xD;
      The aim of this registry is to evaluate the efficacy and safety of the SARS-CoV-2 vaccines in&#xD;
      patients with rheumatic diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>COVID-19 Vaccine efficacy</measure>
    <time_frame>12 month</time_frame>
    <description>Number of patients who develop SARS-CoV-2 infection after vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>COVID-19 Vaccine safety</measure>
    <time_frame>12 month</time_frame>
    <description>Number of patients who develop adverse events asssociated with vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New immunomediated events</measure>
    <time_frame>12 month</time_frame>
    <description>Number of patients who develop new immunomediated events asssociated with vaccination. Description of the events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flare</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients who develop a flare asssociated with vaccination. Description</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the rheumatic disease treatment</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in the rheumatic disease treatment associated with vaccination, and study its influence on the efficacy (number of patients who develop SARS-CoV-2 infection after vaccination) and safety (number of patients who develop adverse events asssociated with vaccination) of the vaccine for SARS-CoV-2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine efficacy among patients with immune mediated and non-immune mediated rheumatic diseases</measure>
    <time_frame>12 months</time_frame>
    <description>Differences in the efficacy/safety profile of SARS-CoV-2 vaccine among patients with immune mediated and non-immune mediated rheumatic diseases.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Rheumatic Diseases</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 Vaccine</intervention_name>
    <description>Patients with rheumatic diseases who have been vaccinated for COVID-19</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with rheumatic diseases who have been vaccinated for COVID-19 in Argentine or any&#xD;
        country&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥ 18 years of age.&#xD;
&#xD;
          -  Diagnosis of rheumatic disease treated or not with immunosuppressive agents&#xD;
&#xD;
          -  Patients who have received at least one dose of a SARS-CoV-2 vaccine&#xD;
&#xD;
          -  Signature of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who express their desire not to participate in the study or who are unable to&#xD;
             give their informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolina Isnardi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unidad de Investigación Sociedad Argentina Reumatología</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carolina Isnardi, MD</last_name>
    <phone>+5491169583394</phone>
    <email>carolina.isnardi@reumatologia.org.ar</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guillermo Pons-Estel, PhD, MD</last_name>
    <phone>+5493412644125</phone>
    <email>unisar@reumatologia.org.ar</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sociedad Argentina de Reumatología</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <state>Caba</state>
        <zip>1022</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Posn-Estel, PhD</last_name>
      <phone>+5493412644125</phone>
      <email>unisar@reumatologia.org.ar</email>
    </contact>
    <contact_backup>
      <last_name>Carolina Isnardi, MD</last_name>
      <phone>+541169583394</phone>
      <email>carolina.isnardi@reumatologia.org.ar</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sociedad Argentina de Reumatologia</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1022</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Isnardi, MD</last_name>
      <phone>1169583394</phone>
      <email>carolina.isnardi@reumatologia.org.ar</email>
    </contact>
    <contact_backup>
      <last_name>Guillermo Pons Estel, MD</last_name>
      <email>unisar@reumatologia.org.ar</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 12, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID-19 Vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

